Nothing Special   »   [go: up one dir, main page]

WO2009113436A1 - Procédé de renforcement de l'activité anticancéreuse d'un rayonnement radioactif au moyen d'un inhibiteur du gène fgf33 en combinaison avec une irradiation par le rayonnement radioactif, et procédé de réduction des effets secondaires du rayonnement radioactif - Google Patents

Procédé de renforcement de l'activité anticancéreuse d'un rayonnement radioactif au moyen d'un inhibiteur du gène fgf33 en combinaison avec une irradiation par le rayonnement radioactif, et procédé de réduction des effets secondaires du rayonnement radioactif Download PDF

Info

Publication number
WO2009113436A1
WO2009113436A1 PCT/JP2009/054104 JP2009054104W WO2009113436A1 WO 2009113436 A1 WO2009113436 A1 WO 2009113436A1 JP 2009054104 W JP2009054104 W JP 2009054104W WO 2009113436 A1 WO2009113436 A1 WO 2009113436A1
Authority
WO
WIPO (PCT)
Prior art keywords
fgfr3
inhibitor
radiation
gene
cancer
Prior art date
Application number
PCT/JP2009/054104
Other languages
English (en)
Japanese (ja)
Inventor
丹沢秀樹
Original Assignee
国立大学法人千葉大学
高信化学株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人千葉大学, 高信化学株式会社 filed Critical 国立大学法人千葉大学
Priority to JP2010502783A priority Critical patent/JPWO2009113436A1/ja
Publication of WO2009113436A1 publication Critical patent/WO2009113436A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a method for enhancing the anticancer effect of radiation and a method for reducing side effects by using a FGFR3 gene inhibitor in combination with irradiation.
  • radiation therapy As part of cancer treatment, radiation therapy is known that uses the ionizing action of radiation such as X-rays and ⁇ -rays to control malignant tumors. Radiation therapy aims to focus the cancer locally without complications by concentrating the dose locally on the cancer and reducing the dose to surrounding normal tissue. Radiation therapy is effective not only for radical radiation therapy but also for palliative and symptomatic treatment. In any case, in order to achieve the above objectives, an appropriate radiation treatment plan including the irradiation field, irradiation method, dose splitting method, combination therapy, etc. will be established for each case. When planning radiation therapy, the patient's age, general condition (PS), primary lesion, stage, histopathology, extent of lesion development, risk organ location, radical or symptomatic or palliative, Consider the details of treatment, complications, etc.
  • PS general condition
  • the FGFR family 1 is classified in terms of connectivity and tissue distribution.
  • the FGFR protein is located in the extracellular region and consists of three immunoglobulin-like domains, a cytoplasmic tyrosine kinase, and a hydrophobic signal.
  • Fibroblast growth factor receptor 3 (FGFR3) has been shown to inhibit chondrocyte proliferation and differentiation. It is.
  • FGFR3 active mutations are known to develop soft bone dysplasia and lethal osteodysplasia, which are short stature chondrogenic dysplasias. There have also been reports of cases of skull fusion due to FGFR3 mutations.
  • FGFR3 gene has been reported to be increased in squamous cell carcinoma, bladder cancer and hepatocellular carcinoma, and when it is overexpressed in multiple myeloma, apoptosis is suppressed and proliferation is increased. Disclosure of the invention
  • an object of the present invention is to provide a radiation therapy effect enhancing agent combined radiotherapy capable of enhancing an anticancer effect by radiation therapy.
  • the inventors succeeded in identifying a gene group involved in radiation resistance, and focusing on a specific gene from these groups, It has been found that the combined use of the inhibitor of the gene product enables enhancement of the radiotherapy effect and reduction of side effects, and the present invention has been completed.
  • the present invention includes the following.
  • a radiation therapeutic effect enhancer comprising a fibroblast growth factor receptor 3 (FGFR3) inhibitor as an active ingredient.
  • FGFR3 fibroblast growth factor receptor 3
  • the above FGFR3 inhibitor is N-2-[[4- (Jetylamino) butyl] amino-6- (3,5-dimethoxyphenyl) pyrid [2,3_d] pyrimidine-7-yl] _N
  • the present invention also includes a method for treating cancer.
  • the cancer treatment method according to the present invention includes a step of administering a composition comprising a fibroblast growth factor receptor 3 (FGFR3) inhibitor as an active ingredient to a radiation treatment target patient.
  • FGFR3 inhibitor a substance that inhibits autophosphorylation of FGFR3 is preferably used.
  • N-2 _ [[4- (Jetylamino) ptyl] amino-6- (3,5-dimethyl) It is more preferable to use toxiphenyl) pyrid [2,3-d] pyrimidine-7-yl] _] '-(1,1-dimethylethyl) urea.
  • the administration method and administration route of the FGFR3 inhibitor are not particularly limited.
  • the radiotherapy for the patient may be performed before the administration of the FGFR3 inhibitor, at the same time as the administration of the FGFR3 inhibitor, or after the administration of the FGFR3 inhibitor.
  • the cancer to be treated is not particularly limited.
  • Examples include sarcomas, soft tissue sarcomas, neuroblastomas, Wilms tumors, retinoblastomas, melanomas, and daliomas.
  • FIG. 1 is a characteristic diagram showing the relationship between the survival rate and the X-ray irradiation dose of squamous cell carcinoma cell lines HSC2, HSC3, HSC4, Ca9-22, 0K92, and HO-1-u-1.
  • Figure 2 shows the results of a pathway analysis of 1 67 genes as a group of genes in which a 5-fold or higher expression was observed in the radiation resistant strain (HSC2) compared to the radiation sensitive strain (HSC3). It is a characteristic view which shows a network.
  • FIG. 3 is a characteristic diagram showing the network obtained as a result of further narrowing down the network shown in FIG. 2 by the cancer function.
  • FIG. 4 is a characteristic diagram showing the relationship between the irradiation dose and the elapsed time after irradiation and the expression level of the FGFR3 gene.
  • FIG. 5 is a characteristic diagram (A) showing the inhibition of FGFR3 gene expression by siRNA against the FGFR3 gene, and a photograph showing the protein expression level.
  • Figure 6 shows the results for the radiation-resistant strain when PD173074, an inhibitor of FGFR3, was administered. It is a characteristic view which shows the X-ray sensitivity enhancement effect.
  • FIG. 7 is a characteristic diagram showing the effect of enhancing X-ray sensitivity in a cell line showing moderate resistance to radiation when PD173074, an inhibitor of FGFR3, is administered.
  • FIG. 8 is a characteristic diagram showing the X-ray sensitivity enhancement effect in a radiation-sensitive strain when PD173074, an inhibitor of FGFR3, was administered.
  • FIG. 9 is a characteristic diagram showing the tumor cell growth inhibitory effect when combined with administration of PD173074, an FGFR3 inhibitor, and X-ray irradiation for mouse transplantation radiation-resistant cancer.
  • the radiotherapy capable of enhancing the radiotherapy effect includes, for example, X-ray, gamma ray, electron beam, proton beam, helium beam, carbon ion beam, neon ion beam, argon ion beam, silicon ion beam, A treatment method in which radiation such as negative pion beams or neutron beams is irradiated directly or in a divided manner (eg, several times a day, several times over a period of 1 to 2 months). It is.
  • the initial energy of radiation can be appropriately selected according to the size, condition, or location of the tumor of the patient, etc., or the surrounding conditions, but is usually about 100 to 500 Me V / n. Preferably about 200-300 Me VZn, most preferably about 29 OMe V, n.
  • the radiation dose to the patient can be appropriately selected according to the size, state or location of the tumor of the patient, etc., or the surrounding conditions, but is usually about 0.1 to 100 Gy.
  • the irradiation rate of radiation to a patient or the like is usually about 0.05 to 50 Gy / "min, preferably Is about 0.5-1 OGy / min, most preferably about 3 Gy / min, and the energy (linear energy transfer: LET) that the radiation gives to the tissue is the size and condition of the patient's tumor Or it can be appropriately selected according to the site, etc., but is usually about 50 to 70 ke VZ / m, preferably about 50 to 60 ke ⁇ , and most preferably about 50 ke V m.
  • the tumor to be treated by radiation therapy is not particularly limited.
  • the radiotherapeutic effect enhancer according to the present invention can increase the therapeutic effect in the radiotherapy as described above. Therefore, since the therapeutic agent for enhancing radiotherapy effect according to the present invention can increase the therapeutic effect in the radiotherapy as described above, a high therapeutic effect can be expected even when the radiation dose is reduced.
  • the radiotherapy effect-enhancing agent according to the present invention comprises a fibroblast growth factor receptor 1 3 (FGFR3) inhibitor as an active ingredient.
  • FGFR3 fibroblast growth factor receptor 1 3
  • the present invention can further enhance the radiosensitivity by inhibiting the activity of the FGFR3 gene product, FGFR3, even in patients who have moderate tolerance to radiation and patients who are sensitive to radiation. Based on these new findings.
  • An FGFR3B inhibitor is a substance that significantly inhibits FGFR3 signaling.
  • any substance may be used as the FGFR3B inhibitor as long as it can significantly reduce FGFR3B signal transduction.
  • examples of the FGFR3 inhibitor include substances that reduce the expression level of the FGFR3 gene, substances that inhibit the mRNA of the FGFR3 gene, substances that inhibit the FGFR3 gene at the protein level, and the like.
  • known substances that are currently clinically used as FGFR3 inhibitors can be used.
  • FGFR3 inhibitors include, for example, N-2-[[4- (Jetylamino) butyl] amino-6- (3,5-dimethoxyphenyl) pyrid [2,3-d] pyrimidine-7- -N '-(1,1-dimethylethyl) urea, ie PD173074
  • the IC 5 of PD173074 Is known to inhibit the cell cycle of G0 / G1 phase and to inhibit FGFR3 autophosphorylation in FGFR3-expressing cells.
  • the selectivity of PD173074 for FGFR3 is about 100 times higher than VEGF receptor, IGF-1 receptor, and MAPKs.
  • PD173074 inhibits autophosphorylation of endogenous FGFRl (IC 5 ⁇ 5 ⁇ M) and overexpressed VEGFR2 (IC 50 ⁇ 200 ⁇ M) in vitro in ⁇ 3 ⁇ 3 cells, and FGF in mice in vivo. And have been shown to inhibit VEGF-induced angiogenesis.
  • PD173074 is described in Koziczak, M., et al. 2004. Oncogene 23, 3501. Trudel, S., et al. 2004. Blood 103, 3521. Skaper, SD, et al. 2000. J. Neurochera. 75, 1520 Reference can be made to Mohammadi, M., et al. 1998. E B0 J. 17, 5896.
  • FGFR3 inhibitor examples include siRNA (small interfering RNA), antisense RNA, ribozyme, and all vector DNAs capable of producing these RNAs for the FGFR3 gene.
  • siRNA small interfering RNA
  • antisense RNA antisense RNA
  • ribozyme ribozyme
  • all vector DNAs capable of producing these RNAs for the FGFR3 gene can inhibit or suppress the expression of the FGFR3 gene.
  • the siRNA used as an FGFR3 inhibitor is a small double-stranded RNA containing a sequence that is complementary to the mRNA corresponding to the FGFR3 gene (that is, the mRNA encoded by the gene) or its alternatively spliced mRNA.
  • the mRNA or its alternatively spliced mRNA is selectively processed through the formation of an RNA-nuclease complex (RNA induced silencing complex or RISC).
  • RNA-nuclease complex RNA induced silencing complex or RISC
  • siRNA may be derived from its precursor double-stranded RNA (shRNA) through processing by Dicer, an intracellular RNase.
  • shRNA is Double-stranded RNA having a loop between the sense strand sequence and the antisense strand sequence of siRNA, preferably 1-6, preferably 2-4 polyU overhangs at its 3 'end including.
  • the shRNA is processed into siRNA by a dicer belonging to the RNase III family, and then siRNA is stranded, and its sense strand RNA forms a complex (RISC) with RNase H, thereby siRNA.
  • RISC complex
  • the target mRNA having a sequence complementary to the sequence is cleaved, and as a result, the expression of the FGFR3 gene is suppressed.
  • both the above siRNA and its precursor shRNA can be used as the FGFR3 inhibitor in the present invention.
  • siRNA or vectors can be complexed with and used with ribosomes such as lipofectamine, lipofectin, selfectin and other positively charged ribosomes (eg, positively charged cholesterol) or microcapsules (eg, Nakanishi Mamoru et al., Protein Nucleic Acid Enzymes, 44, 11, 48-54, 1999; Clinical Cancer research 59: 4325-4333, 1999; Wu et al., J. Biol. Chem. 262: 4429, 1987).
  • ribosomes such as lipofectamine, lipofectin, selfectin and other positively charged ribosomes (eg, positively charged cholesterol) or microcapsules (eg, Nakanishi Mamoru et al., Protein Nucleic Acid Enzymes, 44, 11, 48-54, 1999; Clinical Cancer research 59: 4325-4333, 1999; Wu et al., J. Biol. Chem. 262: 4429, 1987).
  • Positively charged ribosomes are preferably used because the cell membrane is negatively charged, but it is assumed that the positively charged ribosome-nucleic acid complex is transferred into the cytoplasm or nucleus after being incorporated into the cell by endocytosis. Is done.
  • the therapeutic nucleic acid is about
  • nanoparticles can also be encapsulated in nanoparticles of 500 nm or less.
  • nanoparticles include hollow nanoparticles formed from hepatitis B virus envelope L particles.
  • Nucleic acids are encapsulated in the particles by an electrical mouth position. In this case, the nucleic acid-encapsulated particles are Can be delivered to the liver (T. Yamada et al.,
  • nucleic acid When encapsulating a nucleic acid in a liposome, the nucleic acid is treated with protamine sulfate to cause condensation to form a nucleic acid-protein complex, and then encapsulated in a positively charged lipid or polymer micelle.
  • Ribosome-nucleic acid complexes can be obtained, for example, by the reverse phase evaporation method (F. Szoka et al., Biochim. Biophys.
  • nucleic acid examples include an expression vector containing a DNA sequence encoding the siRNA or a precursor thereof under the control of a promoter.
  • an expression vector is a hairpin vector. This vector includes DNA encoding a hairpin RNA in which the sense strand RNA sequence and the antisense strand RNA sequence are covalently linked via a single-stranded loop sequence, wherein the DNA is transcribed in a cell. Is a vector that forms the hairpin RNA and is processed by Dicer to form the siRNA.
  • Short hairpin RNA (shRNA) as a siRNA precursor transcribed from vector DNA should have an overhang consisting of 2 to 4 U at the 3 ′ end of its antisense strand, and due to the presence of the overhang, Sense strand RNA and antisense strand RNA can increase stability against degradation by nucleases.
  • a plasmid vector contains a drug resistance gene (for example, nemycin resistance gene, ampicillin resistance gene, puromycin resistance gene, hygromycin resistance gene), transcription, in addition to the siRNA-encoding DNA sequence and promoter. It can contain stop sequences, unique restriction sites or multiple cloning sites, replication origins, etc.
  • a drug resistance gene for example, nemycin resistance gene, ampicillin resistance gene, puromycin resistance gene, hygromycin resistance gene
  • transcription in addition to the siRNA-encoding DNA sequence and promoter. It can contain stop sequences, unique restriction sites or multiple cloning sites, replication origins, etc.
  • an adenovirus vector for example, an adenovirus vector, an adeno-associated virus vector, a lentiwinores vector, a retroui / res vector (leukemia winores vector, etc.), a herpes virus vector and the like can be used.
  • the virus vector is preferably of a type lacking self-replicating ability, for example, so as not to cause disease when used in humans.
  • a self-replication ability-deficient adenovirus vector lacking the E1 gene and E3 gene for example, pAdeno-X from Invitrogen
  • Virus vectors can be constructed using methods described in the literature (US Pat. No. 5,252,479, International publication W094 / 13788 etc.).
  • the plasmid vector of the present invention can be introduced into a patient's body in the form of a complex formed with a positively charged liposome such as lipophectamine, lipofectin, self-actin, positively charged cholesterol, etc. (Mr. Nakanishi et al., Supra). Wu et al., Supra).
  • viral vectors can be introduced into cells by introducing them into affected areas and infecting cells (L. Zender et al., Proc. Natl. Acad. Sci. USA (2003), 100: 77797-7802; H. Xia et al., Nature Biotech. (2002), 20: 1006-1010; XF Qin et al., Proc. Natl.
  • adenovirus vectors or adeno-associated virus vectors can introduce genes into various cell types with very high efficiency. This vector is also not integrated into the genome, so its effect is transient and safer than other viral vectors.
  • the antisense nucleic acid used as the FGFR3 inhibitor is either RNA or DNA containing a sequence of mRNA corresponding to the FGFR3 gene, or a sequence complementary to a partial sequence thereof.
  • the partial sequence may include a sequence consisting of about 30 or more, 50 or more, 70 or more, 100 or more, 150 or more, 200 or more, or 250 or more and less than full length nucleotides in the sequence of FGFR3 gene or mRNA.
  • antisense nucleic acid nucleotides In addition to natural nucleotides, antisense nucleic acid nucleotides, antisense nucleic acid nucleotides, antisense nucleic acid nucleotides, antisense nucleic acid nucleotides, antisense nucleic acid nucleotides, antisense nucleic acid nucleotides, antisense nucleic acid nucleotides
  • nucleotides having groups such as (fluorine, chlorine, bromine or iodine), methyl, carboxymethyl or thio groups can be included.
  • Antisense nucleic acids are well-known
  • vector DNA containing the base sequence of the FGFR3 gene is converted into a saddle shape and subjected to polymerase chain reaction (PCR) using primers that sandwich the sequence to be amplified, and then the target sequence.
  • PCR polymerase chain reaction
  • the thus obtained DNA having the amplified target sequence is inserted into a vector, the vector is introduced into a eukaryotic or prokaryotic cell, and antisense RNA can be obtained using the transcription system.
  • the antisense nucleic acid of the present invention can inhibit or suppress transcription or translation by binding to the FGFR3 gene or corresponding mRNA.
  • the antisense nucleic acid may be encapsulated in a positively charged ribosome as described above, or the antisense nucleic acid may be, for example, a strong pol II or pol III promoter. It can be incorporated into a vector (the above mentioned plasmid or viral vector) as controlled.
  • the ribozyme used as an FGFR3 inhibitor is an RNA having catalytic activity and has an activity of cleaving mRNA corresponding to the target FGFR3 gene.
  • Ribozymes include hammerhead ribozymes.
  • the hammerhead ribozyme is a nucleotide sequence that includes a nucleotide sequence that constitutes a sensor site, a nucleotide sequence that can form a cavity that can stably capture Mg 2+ ions only when RNA is bound to the sensor site, and a target RNA cleavage site. Nucleotide sequences comprising regions that are complementary to surrounding sequences can be included.
  • a drug delivery system is constructed by a method such as encapsulating the ribozyme in a ribosome (preferably, a positively charged ribosome) or incorporating it into a virus vector such as an adeno-associated virus. That's right.
  • a ribozyme can be incorporated into a vector so that it can be expressed.
  • Promoters for expressing ribozymes include pol II or pol III promoters.
  • Preferred promoters are pol III promoters, such as tRNA promoters from mammals, more preferably tRNAVal promoters.
  • an antibody used as an FGFR3 inhibitor means an antibody or a functional fragment thereof that inhibits or suppresses the in vivo function of the FGFR3 protein encoded by the FGFR3 gene or a variant thereof.
  • antibodies against FGFR3 protein include monoclonal antibodies, recombinantly produced antibodies, human antibodies, humanized antibodies, chimeric antibodies, single chain antibodies, bispecific antibodies, and synthetic antibodies.
  • functional fragments of the antibody include Fab fragments, F (ab ′) 2 fragments, scFv, and the like.
  • Preferred antibodies suitable for use in the present invention are human or humanized antibodies, particularly human or humanized monoclonal antibodies, that cause little or no side effects from anaphylaxis.
  • the antibody class and subclass can be of any type.
  • IgG, IgM, IgE, IgD, and IgA are included as antibody classes
  • IgG1, IgG2, IgG3, IgG4, IgAl, and IgA2 are included as subclasses.
  • Antibodies may also be derivatized by pegylation, acetylation, glycosylation, amidation, etc.
  • the human antibody can be obtained, for example, by a phage display library method (T. Thomas et al., Mol. Immunol. 33: 1389-1401, 1996) or a method using a human antibody-producing mouse (I. Ishida et al., Cloning Stem Cell 4: 91-102, 2002).
  • a human antibody-producing mouse for example, introduces a human chromosome fragment containing a human antibody-producing gene into a human artificial chromosome, and then incorporates the artificial chromosome into, for example, the mouse embryonic stem cell genome using the microcell method. Transplant into the uterus, give birth to chimeric mice, and create a homozygous offspring mouse that contains the human antibody gene by mating male and female chimeric mice and can therefore produce human antibodies. Therefore, it can be produced.
  • the human antibody-producing transgenic mouse is immunized with the FGFR3 protein as an antigen, and then the spleen is removed, and the spleen cells and mouse myeloma cells are fused to form a hybridoma, and the desired monoclonal antibody is selected. be able to.
  • Delivery of the antibody or fragment thereof to the patient can be accomplished either alone or in the form of the antibody or fragment thereof encapsulated in, for example, ribosomes (preferably positively charged ribosomes), microcapsules or nanoparticles, usually with a suitable carrier (shaped In combination with a non-oral route (for example, intravenous administration or topical administration).
  • ribosomes preferably positively charged ribosomes
  • microcapsules or nanoparticles usually with a suitable carrier (shaped In combination with a non-oral route (for example, intravenous administration or topical administration).
  • the above FGFR3 inhibitors can significantly enhance the anti-cancer effect of radiation therapy when administered together with radiation therapy for patients diagnosed as requiring radiation therapy. Therefore, anticancer effects of radiation therapy can be expected even for carcinoma cases where the effect of radiation therapy has been low.
  • FGFR3 inhibitors reduce the level of radiation resistance, so the dose of irradiated radiation has been reduced. It is possible to expect a therapeutic effect equivalent to or better than. Therefore, side effects caused by radiation therapy can be reduced, or it can be applied to non-indication cases of radiation therapy for reasons such as general condition, and an effective treatment method can be provided for the patient.
  • the FGFR3 inhibitor is preferably administered to patients prior to radiation therapy.
  • the FGFR3 inhibitor can be administered by any appropriate route.
  • Suitable routes include oral, rectal, intranasal, topical (including buccal and sublingual), intravaginal, and parenteral (subcutaneous, intramuscular, intravenous, intradermal, intrathecal and dura mater) Including the outside).
  • the FGFR3 inhibitor can be administered directly or locally to, for example, a tissue in which a tumor is present, or can be administered intravenously, artery, subcutaneously, intramuscularly or intraperitoneally.
  • a tumor can be imaged using any device available in the art, such as nuclear magnetic resonance imaging or computed tomography, and administered directly, for example, by stereotaxic injection.
  • the dose of FGFR3 inhibitor can be 10 to 100 mg / m 2 (body surface area), preferably 10 to It can be 50 mg / tn 2 (body surface area), more preferably 20 to 50 mg / m 2 (body surface area). .
  • Microarray analysis using radiation-resistant and radiation-sensitive strains identified genes that specifically enhanced expression in resistant strains.
  • Affymetrix U133 Plus 2.0 on which 54675 types of probes were immobilized was used.
  • GeneChip Operating Software 1.1 (Affymetrix) and GeneSpring 6.1 (Silicon Genetics) were used as analysis software.
  • HSC2 radiation resistant strain
  • HSC3 radiation sensitive strain
  • Pathway analysis was performed on 1 6 7 genes identified as genes related to radiation resistance narrowed down by microarray analysis, and 1 6 7 genes Then, what kind of network was formed was examined. Specifically, the pathway analysis used software, Ingenuity Pathway Analysis (manufactured by Ingenuity systems). As a result, 40 genes out of 1 6 7 genes
  • the FGFR3 gene was selected as an apparent gene expression inhibitor gene.
  • the raRNA expression status of the FGFR3 gene in the resistant strain (HSC2) and the susceptible strain (HSC3) was confirmed by the Quantitative real-time RT-PCR method with respect to the X-ray irradiation dose and the elapsed time after irradiation (Fig. 4).
  • Fig. 4A shows the relationship between X-ray irradiation dose and mRNA expression level
  • Fig. 4B shows the relationship between elapsed time after X-ray irradiation and mRNA expression level.
  • Figure 4 Shown in A and B
  • the expression of the FGFR3 gene was always increased in the HSC2 resistant strain under X-ray irradiation conditions.
  • siRNA was introduced to examine changes in X-ray resistance.
  • DhamaFECT Dermatacon
  • FGFR3 gene siRNA was introduced into HSC2, and after 96 hours, 200 / 4ml raediura / di sh (0, 2 or 4Gy), 400 / 4ml medium / di sh (6Gy), 800 / Cells were transferred to three 6cra dishes at a rate of 4ml medium / di sh. (8Gy) 24 hours later, irradiated with X-rays, incubated for 8-10 days, and then clonogenic survival assay.
  • clonogenic survival assay cells were stained and fixed with a crystal violet solution (25% methanol added) (Sigma Chemical Co.) on 6 cm dishes after incubation for 8-10 days. Count the number of cell colonies (consisting of more than 50 cells), and set the plating eff iciency to (average viable cell colony number) I (number of cells spread in one dish) of the cells in three dishes.
  • Fig. 5 A As shown in Fig. 5 A, cells transfected with s siRNA against the FGFR3 gene were included in the control group. In comparison, the resistance to X-rays was reduced, and it was considered that the sensitivity to X-rays was increased by suppressing the expression of the FGFR3 gene. This is shown in Fig. B. As can be seen from Fig. 5 B, it was confirmed that the expression of the FGFR3 gene protein was suppressed in the siRNA-transfected cells against the FGFR3 gene, which was considered to be a radiation resistance gene. .
  • DMS0 As the inhibitor solvent, DMS0 was used to dissolve the inhibitor. In the experiment, the DMS0 concentration in the medium was adjusted to 0.1% or less, and the inhibitor was mixed. The inhibitor concentration was 5 nM, 10 nM, 25 nM, 50 nM or ⁇ ⁇ ⁇ .
  • the efficiency obtained by dividing the plating efficiency after irradiation with each dose by the plating efficiency of OGy was plotted as the survival fraction (Clonogenic fractions). Since the inhibitor was dissolved in 0.1% or less of DMS0, 0.1% DMS0 added and untreated HSC2, HSC3 or Ca9_22 cells were used as controls.
  • the results of plotting the survival rate are shown in Figs. Fig. 6 shows the results for the radiation-resistant strain HSC2, Fig. 7 shows the results for Ca9-22, which shows moderate resistance to radiation, and Fig.
  • FIG. 8 shows the results for the radiation-sensitive strain HSC3. is there.
  • Fig. 6 when the function of FGFR3 was inhibited by administration of an FGFR3 inhibitor, it was considered that the sensitivity to X-rays in the radiation resistant strain increased.
  • Fig. 7 it was considered that the sensitivity to X-rays also increased in cell lines that showed moderate resistance to radiation.
  • Fig. 8 it was considered that the sensitivity to X-rays was also increased in the radiation-sensitive strain.
  • HSC2 strain was prepared to 5 ⁇ 10 6 and inoculated subcutaneously into the right thigh of a mouse using a 29G needle (Myjector 1: TERUM0). The mice were bred while observing, and X-ray irradiation and administration of an FGFR3 inhibitor were started when the tumor diameter reached 8-9 mm.
  • FGFR3 inhibitor was administered intraperitoneally at 25 mg / kg.
  • X-ray (4Gy) irradiation was started 2 hours after administration of the FGFR3 inhibitor.
  • Administration of FGFR3 inhibitor and X-ray (4Gy) irradiation were performed once a day for 5 days.
  • a group in which no treatment was performed, a group in which only FGFR3 inhibitor was administered, and a group in which only X-ray (4Gy) irradiation was performed were used as comparison targets.
  • 4Gy indicates X-ray.
  • the growth of tumor cells can be significantly suppressed.
  • the effect of inhibiting the growth of tumor cells when FGFR3 inhibitor administration and X-ray (4Gy) irradiation are used in combination is the effect of tumor cells when FGFR3 inhibitor administration or X-ray (4Gy) irradiation is performed alone. It was so remarkable that it could not be predicted from the growth inhibitory effect.
  • 25 genes with higher reliability were selected as genes related to X-ray resistance. Quantitative for the 25 genes The mRNA expression was confirmed by real-time RT-PCR, and the FGFR3 gene that was highly expressed in the resistant strain and in which the inhibitor was present was selected.
  • the anticancer effect by radiation therapy can be enhanced. Therefore, by using the radiotherapy effect enhancer according to the present invention, for example, a radiotherapy can be performed with a low dose, and a treatment method that reduces the burden on the patient can be provided. Moreover, by using the radiotherapy effect enhancer according to the present invention, for example, radiotherapy with a low dose becomes possible, and side effects due to radiotherapy can be reduced. Furthermore, an effective therapeutic effect overcoming the radiation therapy resistance can be obtained by increasing the radiation therapy effect on the tumor having radiation resistance.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne le renforcement de l'activité anticancéreuse d'une radiothérapie. On réussit à identifier un groupe de gènes impliqué dans la résistance à un rayonnement radioactif. On se concentre sur un gène spécifique parmi le groupe de gènes. Il a été démontré que l'effet thérapeutique de la radiothérapie peut être renforcé et que les effets secondaires de la radiothérapie peuvent être réduits grâce à l'utilisation d'un inhibiteur d'un produit du gène en combinaison avec la radiothérapie. Un agent de renforcement de l'effet thérapeutique de la radiothérapie comprend un inhibiteur de récepteur-3 du facteur de croissance du fibroblaste (FGFR3) comme ingrédient actif.
PCT/JP2009/054104 2008-03-14 2009-02-26 Procédé de renforcement de l'activité anticancéreuse d'un rayonnement radioactif au moyen d'un inhibiteur du gène fgf33 en combinaison avec une irradiation par le rayonnement radioactif, et procédé de réduction des effets secondaires du rayonnement radioactif WO2009113436A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010502783A JPWO2009113436A1 (ja) 2008-03-14 2009-02-26 Ｆｇｆｒ３遺伝子阻害剤の放射線照射併用による放射線の抗癌作用増強法および副作用軽減法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008-066443 2008-03-14
JP2008066443 2008-03-14

Publications (1)

Publication Number Publication Date
WO2009113436A1 true WO2009113436A1 (fr) 2009-09-17

Family

ID=41065105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/054104 WO2009113436A1 (fr) 2008-03-14 2009-02-26 Procédé de renforcement de l'activité anticancéreuse d'un rayonnement radioactif au moyen d'un inhibiteur du gène fgf33 en combinaison avec une irradiation par le rayonnement radioactif, et procédé de réduction des effets secondaires du rayonnement radioactif

Country Status (2)

Country Link
JP (1) JPWO2009113436A1 (fr)
WO (1) WO2009113436A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014051022A1 (ja) * 2012-09-27 2016-08-22 中外製薬株式会社 Ｆｇｆｒ３融合遺伝子およびそれを標的とする医薬

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047244A2 (fr) * 2003-11-07 2005-05-26 Chiron Corporation Inhibition de recepteur fgfr3 et traitement de myelome multiple

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648371A1 (fr) * 2006-04-04 2007-10-11 Pfizer Products Inc. Polytherapie a base de (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047244A2 (fr) * 2003-11-07 2005-05-26 Chiron Corporation Inhibition de recepteur fgfr3 et traitement de myelome multiple

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BERNARD, ROSANNE ST. ET AL.: "Fibroblast Growth Factor Receptors as Molecular Targets in Thyroid Carcinoma.", ENDOCRINOLOGY, vol. 146, 2005, pages 1145 - 1153 *
CHIARUGI, VINCENZO. ET AL.: "Dominant oncogenes, tumor suppressors, and radiosensitivity.", CELLULAR AND MOLECULAR BIOLOGY RESEARCH, vol. 41, 1995, pages 161 - 166 *
ESWARAKUMAR, V.P. ET AL.: "Cellular signaling by fibroblast growth factor receptors.", CYTOKINE & GROWTH FACTOR REVIEWS, vol. 16, 2005, pages 139 - 149 *
GRAND, E.K. ET AL.: "Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.", LEUKEMIA, vol. 18, 2004, pages 962 - 966 *
KAMMASUD, NAPARAT. ET AL.: "Novel inhibitor for fibroblast growth factor receptor tyrosine kinase.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, 2007, pages 4812 - 4818 *
KOZICZAK, MAGDALENA ET AL.: "Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins.", ONCOGENE, vol. 23, 2004, pages 3501 - 3508 *
LI, RONGRONG. ET AL.: "Enhancing radiosensitivity of Hela cells by combining transfection of bcl-2 c-myc ASODNs.", BULLETIN DU CANCER, vol. 93, 2006, pages E119 - E125 *
MOHAMMADI, MOOSA. ET AL.: "Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.", THE EMBO JOURNAL, vol. 17, 1998, pages 5896 - 5904 *
TRUDEL, SUZANNE. ET AL.: "Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.", BLOOD, vol. 103, 2004, pages 3521 - 3528 *
ZHU, LIJUN ET AL.: "Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.", MOLECULAR CANCER THERAPEUTICS, vol. 4, 2005, pages 787 - 798 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014051022A1 (ja) * 2012-09-27 2016-08-22 中外製薬株式会社 Ｆｇｆｒ３融合遺伝子およびそれを標的とする医薬
US10689705B2 (en) 2012-09-27 2020-06-23 Chugai Seiyaku Kabushiki Kaisha FGFR3 fusion gene and pharmaceutical drug targeting same

Also Published As

Publication number Publication date
JPWO2009113436A1 (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
US20080145313A1 (en) Compositions and Methods for the Treatment and Prevention of Neoplastic Disorders
US12060619B2 (en) Treatment of angiogenesis disorders
CA2308565A1 (fr) Sequences pour cibler les cellules metastatiques
CN111304249B (zh) 一种新型CRISPR Cas13a-gRNA表达载体及其应用
Nyati et al. High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer
KR20100077160A (ko) 근육 및 심장 강화제의 타겟으로서 ｔｒｉｍ72의 용도
Takigami et al. Synthetic siRNA targeting the breakpoint of EWS/Fli‐1 inhibits growth of Ewing sarcoma xenografts in a mouse model
EP1062340A2 (fr) Compositions et methodes de traitement et de prevention de troubles metastatiques
JP2023123748A (ja) 転移性癌の診断及び治療の方法
JP4467559B2 (ja) 細胞増殖を阻害する組成物および方法
US20080085279A1 (en) Cancer Treatment
WO2009113436A1 (fr) Procédé de renforcement de l'activité anticancéreuse d'un rayonnement radioactif au moyen d'un inhibiteur du gène fgf33 en combinaison avec une irradiation par le rayonnement radioactif, et procédé de réduction des effets secondaires du rayonnement radioactif
JP2007530431A (ja) 膵臓癌を治療するための組成物および方法
JP5467259B2 (ja) シスプラチン効果増強剤及び抗癌剤キット
JP5578498B2 (ja) 抗癌剤キット及び抗癌剤効果増強剤
KR20050103305A (ko) 포유 동물 세포에 있어서의 ｄｓＲＮＡ에 의한 ＣｐＧ서열로의 메틸화 유도
CN115141827B (zh) Gal-9作为靶点在筛选或制备治疗B细胞淋巴瘤的药物中的应用
EP4286518A1 (fr) Ribozyme de trans-épissage spécifique du cancer exprimant un inhibiteur de point de contrôle immunitaire, et utilisation associée
JP2011500867A (ja) 血管形成を阻害する、または癌を治療するための方法
KR20240139138A (ko) 항-egfr 치료에 대한 반응성 예측용 조성물
Lee et al. IGF-1R blockade strategies in human cancers
JP4797159B2 (ja) 癌転移抑制用組成物
WO2014129895A1 (fr) Moyen et méthode d'augmentation de la sensibilité de cancers à la radiothérapie
WO2017159739A1 (fr) Agent anticancéreux
WO2004046356A1 (fr) Exon 1$g(b) du gene $g(a) du recepteur du pdgf et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09720202

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010502783

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09720202

Country of ref document: EP

Kind code of ref document: A1